This session explores the cutting edge of personalized medicine beyond traditional gene testing, highlighting the clinical integration of next-generation diagnostic technologies. Experts will discuss the promise and practical application of proteomics, metagenomics, circulating tumor DNA (ctDNA), and digital diagnostic tools in delivering more precise, timely, and individualized care.

Industry innovation in diagnostic technologies and targeted treatment strategies drives progress in personalized medicine. But the path to market is fraught with obstacles. Pioneering investors and executives reflect on how to deal with challenges and uncertainty in an increasingly variable development and market environment.

By detecting molecular cancer signals in blood samples of seemingly healthy patients, a new generation of early cancer detection tests promises to put more patients on the path to personalized cancer treatment, sooner, when cancer may be more effectively treated. What might this mean for the future of cancer care? Leading voices discuss.

Machine Learning and Artificial intelligence technologies can drive biomarker discovery and validation and more readily explore divergent effects of preventive and treatment interventions across extensive data sets. What might this mean for the future of personalized medicine and what is being done to realize that future?